M&A Deal Summary

InvoX Pharma Acquires F-star Therapeutics

On June 23, 2022, InvoX Pharma acquired life science company F-star Therapeutics for 161M USD

Acquisition Highlights
  • This is InvoX Pharma’s 1st transaction in the Life Science sector.
  • This is InvoX Pharma’s largest (disclosed) transaction.
  • This is InvoX Pharma’s 1st transaction in the United Kingdom.

M&A Deal Summary
Date 2022-06-23
Target F-star Therapeutics
Sector Life Science
Buyer(s) InvoX Pharma
Deal Type Add-on Acquisition
Deal Value 161M USD
Advisor(s) Morgan Stanley (Financial)
Mintz Levin Cohn Ferris Glovsky and Popeo PC (Legal)

Target

F-star Therapeutics

Cambridge, United Kingdom
F-star Therapeutics is a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can live longer and improved lives. F-star is committed to working towards a future free from cancer and other serious diseases, through the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in treatments. F-star Therapeutics is based in Cambridge, United Kingdom.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

InvoX Pharma

London, United Kingdom
Category Company
Sector Life Science
DESCRIPTION

InvoX Pharma focuses on R&D and business development activities outside of China, with a core focus on oncology and respiratory therapeutics. InvoX Pharma is based in London, United Kingdom.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (United Kingdom) 1 of 1
Year (2022) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal